EP-01: Association of genetic polymorphisms of OATP with susceptibility to hepatocellular carcinoma in hepatitis C patients who achieved SVR by direct acting antivirals

Abstract

OBJECTIVES: Simeprevir, daclatasvir, ledipasvir, paritaprevir and ritonavir are all substrates and inhibitors of the organic anion transporting polypeptide (OATP1B1 transporter, whereas sofosbuvir, ombitasvir and dasabuvir are not substrates. The purpose of this study is to evaluate the association of organic anion transporting polypeptide (OATP) gene polymorphism and hepatocellular carcinoma in Hepatitis C patients who achieved SVR by direct acting antivirals. MATERIALS & METHODS: Four single-nucleotide polymorphisms (SNPs) (388 A>G, 521 T>C, 334 T>G, and 699 G>A) within the OATP gene were genotyped by PCR-RFLP in 200 patients with chronic HCV infection (CHC) treated with DAAs, Laboratory work up and abdominal ultrasound was performed at baseline, at 12 weeks after end of treatment and then at every 6 months of follow up (FU). RESULTS: The overall SVR12 rate was 99.5%. The SVR12 rate was similar between the patients with HCC and those without HCC (100% vs 99.4%, p=0.49). HCC developed in 10 (5%) of the patients, approximately 11 (6-36 months) after the end of the treatment. No significant differences were found regarding OATP gene polymorphisms among the case groups (including CHC and HCC) and no matter in comparisons of alleles, genotypes, or haplotypes. Similar insignificant results were also observed when subgroup analyses were performed in different gender. CONCLUSION: Our observation suggests that SNPs 388 A>G, 521 T>C, 334 T>G, and 699 G>A of OATP gene might not contribute to the development of HCC in Hepatitis C patients who achieved SVR by direct acting antivirals. Keywords: Hepatitis C, hepatocellular carcinoma, organic anion transporting polypeptide.

Figure 1

(A) Brown pigments can be seen in liver biopsy with hemotoxylin&eosin stain (x200). (B) Excessive iron deposition is demonstrated by Prussian blue staining (x400).

Figure 1

Relationship between Δ-LS and F scores after AVT.

Figure 1

ROC curve of HbeAg (+) patients with fibrozis >2.

Figure 1.

Figure 1

Patient enrollment and classification (HAV, Hepatitis A virus; n, number).

Figure 1

Survival comparison of sarcopenics with non-sarcopenics

Figure 1

HCC lesion on MRI, hypointense mass in the hepatobiliary phase (A), and contrast-enhancing mass in the arterial phase (B).

Figure 1

A brown nodular lesion, 5–6 mm in size, on the medial aspect of the forearm (A), a purple tumoral lesion in the oral mucosa, 2–3 cm in size, on the hard palate (B).

Figure 1

Triglyceride level in subgroups of NAFLD and NAPS